Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EGRX | US
-0.01
-0.23%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2023
19/09/2024
4.27
4.44
4.54
4.27
Eagle Pharmaceuticals Inc. a pharmaceutical company focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104 a dantrolene sodium to treat organophosphate exposure; PEMFEXY a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin SA for the development and commercialization rights to CAL02 an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake New Jersey.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
88.2%1 month
81.4%3 months
79.6%6 months
82.7%5.07
11.34
0.22
0.28
0.17
2.01
0.44
0.91
62.33M
55.33M
55.33M
-
15.94
-87.10
-12.80
4.88
4.91
5.07
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.32
Range1M
1.90
Range3M
2.82
Rel. volume
0.42
Price X volume
145.15K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Qilian International Holding Group Limited | QLI | Drug Manufacturers-Specialty & Generic | 8.08 | 48.23M | 1.00% | n/a | 1.35% |
DURECT Corporation | DRRX | Drug Manufacturers-Specialty & Generic | 1.37 | 42.52M | 1.48% | n/a | 318.92% |
Provectus Biopharmaceuticals Inc | PVCT | Drug Manufacturers-Specialty & Generic | 0.0899 | 37.75M | 1.01% | n/a | 0.00% |
Cannex Capital Holdings Inc | ARRXF | Drug Manufacturers-Specialty & Generic | 0.1318 | 33.72M | n/a | 0.50% | |
India Globalization Capital Inc | IGC | Drug Manufacturers-Specialty & Generic | 0.3487 | 26.37M | 2.56% | n/a | 4.33% |
Lipocine Inc | LPCN | Drug Manufacturers-Specialty & Generic | 4.77 | 25.51M | -4.79% | n/a | 0.00% |
MEI Pharma Inc | MEIP | Drug Manufacturers-Specialty & Generic | 3.14 | 20.92M | 3.29% | 0.77 | 22.86% |
Flora Growth Corp. Common Stock | FLGC | Drug Manufacturers-Specialty & Generic | 1.42 | 18.98M | 35.24% | n/a | 76.81% |
Cumberland Pharmaceuticals Inc | CPIX | Drug Manufacturers-Specialty & Generic | 1.28 | 18.04M | 2.40% | n/a | 81.86% |
Guardion Health Sciences Inc | GHSI | Drug Manufacturers-Specialty & Generic | 10.85 | 13.93M | 3.63% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ILAG | ILAG | Building Products & Equipment | 1.04 | 18.78M | 13.06% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.02 | 12.43M | -7.27% | n/a | 16.03% |
The Dixie Group Inc | DXYN | Textile Manufacturing | 0.737 | 11.34M | 3.80% | n/a | 422.08% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6475 | 6.16M | -2.76% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.315 | 4.97M | -1.56% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.42 | 3.63M | 1.43% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.751 | 1.10M | 24.54% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 915.21K | -8.33% | n/a | -37.05% |
Blackstone/GSO Senior Floating Rate Term Fund | BSL | Textile Manufacturing | 14.31 | 0 | 0.35% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 2.01 | 16.67 | Cheaper |
Ent. to Revenue | 0.44 | 309.37 | Cheaper |
PE Ratio | 5.07 | 29.14 | Cheaper |
Price to Book | 0.22 | 12.81 | Cheaper |
Dividend Yield | - | 2.80 | - |
Std. Deviation (3M) | 79.63 | 75.12 | Par |
Debt to Equity | 0.28 | -0.93 | Expensive |
Debt to Assets | 0.17 | 0.45 | Cheaper |
Market Cap | 55.33M | 5.22B | Emerging |